BoB In South Florida: Anthony Japour, M.D., iTolerance

We love to hear from our listeners. Send us a message. On this week"s episode of the Business of Biotech -- part three in a four part series recorded in-person at Catalyst Pharmaceuticals" Miami headquarters -- Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance"s work toward a cure for Type 1 diabetes that doesn"t require chronic immunosuppression. Anthony also provides insights on overcoming CMC challenges and how to bypass avoidable detours, the funding climate for preclinical biotechs, and operating in South Florida.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/